Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$7.0M
Filings
136
Firms Hired
5
Active Period
2016–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. H.R.10571, Surge to Save Newborns Act. H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Support of reauthorization of priority review voucher program. Pub. L. No. 119-21, One Big Beautiful Bill Act, provisions regarding orphan drugs.
Client expense: — · Firm income: $80,000
Matched citations: H.R.10571
H.R.10571, Surge to Save Newborns Act.
Client expense: — · Firm income: $80,000
Matched citations: H.R.10571
H.R.1414, Camerons Law, to restore the amount of the Orphan Drug Tax Credit.
Client expense: — · Firm income: $80,000
Matched citations: H.R.1414
New Era of Preventing End-Stage Kidney Disease Act
2026 · third_quarter · Firm: ALSTON & BIRD LLP
Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. H.R.10571, Surge to Save Newborns Act. H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Support of reauthorization of priority review voucher program. Pub. L. No. 119-21, One Big Beautiful Bill Act, provisions regarding orphan drugs.
Client expense: — · Firm income: $80,000
Matched citations: H.R.1518
New Era of Preventing End-Stage Kidney Disease Act
2026 · third_quarter · Firm: ALSTON & BIRD LLP
H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Pub. L. No. 119-21, One Big Beautiful Bill Act, provisions regarding orphan drugs, Medicare and Medicaid.
Client expense: — · Firm income: $80,000
Matched citations: H.R.1518
Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. H.R.10571, Surge to Save Newborns Act. H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Support of reauthorization of priority review voucher program. Pub. L. No. 119-21, One Big Beautiful Bill Act, provisions regarding orphan drugs.
Client expense: — · Firm income: $80,000
Matched citations: H.R.946
Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Pub. L. No. 119-21, One Big Beautiful Bill Act, provisions regarding orphan drugs. Most-Favored Nation and International Reference Pricing proposals. PDUFA/regulatory review process.
Client expense: — · Firm income: $80,000
Matched citations: H.R.946
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2026 · third_quarter · Firm: TRAVERE THERAPEUTICS
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.H.R. 9509, the Kidney Disease Education Expansion Act
Client expense: $100,000 · Firm income: —
Matched citations: H.R.1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2026 · third_quarter · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA); H.R. 10359, Priority for Pediatric Cures Act to make PRV permanent
Client expense: $100,000 · Firm income: —
Matched citations: H.R.1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2026 · third_quarter · Firm: TRAVERE THERAPEUTICS
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related implementation provisions in H.R.1, One Big Beautiful Bill Act; pharmaceutical tariffs, specifically related to orphan drugs
Client expense: $100,000 · Firm income: —
Matched citations: H.R.1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2026 · third_quarter · Firm: TRAVERE THERAPEUTICS
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
Client expense: $100,000 · Firm income: —
Matched citations: H.R.1
Priority for Pediatric Cures Act
2026 · third_quarter · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA); H.R. 10359, Priority for Pediatric Cures Act to make PRV permanent
Client expense: $100,000 · Firm income: —
Matched citations: H.R. 10359
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act; end-stage renal disease policy and rare kidney disease; HR 10571, the Surge to Save Newborns Act
Client expense: $100,000 · Firm income: —
Matched citations: HR 10571
Mikaela Naylon Give Kids a Chance Act
2026 · third_quarter · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA); H.R. 10359, Priority for Pediatric Cures Act to make PRV permanent
Client expense: $100,000 · Firm income: —
Matched citations: HR 1262
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related implementation provisions in H.R.1, One Big Beautiful Bill Act; pharmaceutical tariffs, specifically related to orphan drugs
Client expense: $100,000 · Firm income: —
Matched citations: H.R. 1414
New Era of Preventing End-Stage Kidney Disease Act
2026 · third_quarter · Firm: TRAVERE THERAPEUTICS
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act; end-stage renal disease policy and rare kidney disease; HR 10571, the Surge to Save Newborns Act
Client expense: $100,000 · Firm income: —
Matched citations: HR 1518
Newborn Screening Saves Lives Reauthorization Act of 2025
2026 · third_quarter · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA); H.R. 10359, Priority for Pediatric Cures Act to make PRV permanent
Client expense: $100,000 · Firm income: —
Matched citations: HR 4709
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA); H.R. 10359, Priority for Pediatric Cures Act to make PRV permanent
Client expense: $100,000 · Firm income: —
Matched citations: H.R. 9102
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
Client expense: $100,000 · Firm income: —
Matched citations: HR 946
Kidney Disease Education Access Expansion Act of 2026
2026 · third_quarter · Firm: TRAVERE THERAPEUTICS
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.H.R. 9509, the Kidney Disease Education Expansion Act
Client expense: $100,000 · Firm income: —
Matched citations: H.R. 9509
Drug Competition Enhancement Act
2026 · third_quarter · Firm: TRAVERE THERAPEUTICS
S.1040, to prohibit product hopping and for other purposes; proposals regarding patent thickets. S. 2658, Medication Affordability and Patent Integrity Act
Client expense: $100,000 · Firm income: —
Matched citations: S.1040
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
Client expense: $100,000 · Firm income: —
Matched citations: S. 1862
Medication Affordability and Patent Integrity Act
2026 · third_quarter · Firm: TRAVERE THERAPEUTICS
S.1040, to prohibit product hopping and for other purposes; proposals regarding patent thickets. S. 2658, Medication Affordability and Patent Integrity Act
Client expense: $100,000 · Firm income: —
Matched citations: S. 2658
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA); H.R. 10359, Priority for Pediatric Cures Act to make PRV permanent
Client expense: $100,000 · Firm income: —
Matched citations: S 932
H.R.1414, Camerons Law, to restore the amount of the Orphan Drug Tax Credit.
Client expense: — · Firm income: $70,000
Matched citations: H.R.1414
Source: Senate LDA